-
1
-
-
33847096349
-
Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management
-
Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49(5):330-352.
-
(2007)
Prog. Cardiovasc. Dis.
, vol.49
, Issue.5
, pp. 330-352
-
-
Takemura, G.1
Fujiwara, H.2
-
2
-
-
10844293438
-
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
-
Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 2004, 91(10):1775-1781.
-
(2004)
Br. J. Cancer
, vol.91
, Issue.10
, pp. 1775-1781
-
-
Matsumura, Y.1
Hamaguchi, T.2
Ura, T.3
Muro, K.4
Yamada, Y.5
Shimada, Y.6
Shirao, K.7
Okusaka, T.8
Ueno, H.9
Ikeda, M.10
Watanabe, N.11
-
3
-
-
0141548120
-
Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data
-
Rihova B., Strohalm J., Prausova J., Kubackova K., Jelinkova M., Rozprimova L., Sirova M., Plocova D., Etrych T., Subr V., Mrkvan T., Kovar M., Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release 2003, 91(1-2):1-16.
-
(2003)
J. Control. Release
, vol.91
, Issue.1-2
, pp. 1-16
-
-
Rihova, B.1
Strohalm, J.2
Prausova, J.3
Kubackova, K.4
Jelinkova, M.5
Rozprimova, L.6
Sirova, M.7
Plocova, D.8
Etrych, T.9
Subr, V.10
Mrkvan, T.11
Kovar, M.12
Ulbrich, K.13
-
4
-
-
0032975042
-
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
-
Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17(2):478-484.
-
(1999)
J. Clin. Oncol.
, vol.17
, Issue.2
, pp. 478-484
-
-
Tolcher, A.W.1
Sugarman, S.2
Gelmon, K.A.3
Cohen, R.4
Saleh, M.5
Isaacs, C.6
Young, L.7
Healey, D.8
Onetto, N.9
Slichenmyer, W.10
-
5
-
-
85081448520
-
-
National Cancer Institute: Breast cancer PDQ treatment,<> Access date 10/29/2009.
-
National Cancer Institute: Breast cancer PDQ treatment, 2007, <> Access date 10/29/2009. http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional.
-
(2007)
-
-
-
6
-
-
33845347364
-
Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients
-
Querzoli P., Pedriali M., Rinaldi R., Lombardi A.R., Biganzoli E., Boracchi P., Ferretti S., Frasson C., Zanella C., Ghisellini S., Ambrogi F., Antolini L., Piantelli M., Iacobelli S., Marubini E., Alberti S., Nenci I. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin. Cancer Res. 2006, 12(22):6696-6701.
-
(2006)
Clin. Cancer Res.
, vol.12
, Issue.22
, pp. 6696-6701
-
-
Querzoli, P.1
Pedriali, M.2
Rinaldi, R.3
Lombardi, A.R.4
Biganzoli, E.5
Boracchi, P.6
Ferretti, S.7
Frasson, C.8
Zanella, C.9
Ghisellini, S.10
Ambrogi, F.11
Antolini, L.12
Piantelli, M.13
Iacobelli, S.14
Marubini, E.15
Alberti, S.16
Nenci, I.17
-
7
-
-
68849115626
-
Micrometastases or isolated tumor cells and the outcome of breast cancer
-
Boer M.d., Deurzen C.H.v., Dijck J.A.v., Borm G.F., Diest P.J.v., Adang E.M., Nortier J.W., Rutgers E.J., Seynaeve C., Menke-Pluymers M.B., Bult P., Tjan-Heijnen V.C. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 2009, 361(7):653-663.
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.7
, pp. 653-663
-
-
Boer, M.1
Deurzen, C.2
Dijck, J.3
Borm, G.F.4
Diest, P.5
Adang, E.M.6
Nortier, J.W.7
Rutgers, E.J.8
Seynaeve, C.9
Menke-Pluymers, M.B.10
Bult, P.11
Tjan-Heijnen, V.C.12
-
8
-
-
0024351669
-
Turnover and metabolism of hyaluronan
-
discussion 53-49, 281-285
-
Fraser J.R., Laurent T.C. Turnover and metabolism of hyaluronan. Ciba Found. Symp. 1989, 143:41-53. discussion 53-49, 281-285.
-
(1989)
Ciba Found. Symp.
, vol.143
, pp. 41-53
-
-
Fraser, J.R.1
Laurent, T.C.2
-
9
-
-
0035132865
-
CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation
-
Ahrens T., Assmann V., Fieber C., Termeer C., Herrlich P., Hofmann M., Simon J.C. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Invest. Dermatol. 2001, 116(1):93-101.
-
(2001)
J. Invest. Dermatol.
, vol.116
, Issue.1
, pp. 93-101
-
-
Ahrens, T.1
Assmann, V.2
Fieber, C.3
Termeer, C.4
Herrlich, P.5
Hofmann, M.6
Simon, J.C.7
-
10
-
-
0030790353
-
High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival
-
Dietrich A., Tanczos E., Vanscheidt W., Schopf E., Simon J.C. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur. J. Cancer 1997, 33(6):926-930.
-
(1997)
Eur. J. Cancer
, vol.33
, Issue.6
, pp. 926-930
-
-
Dietrich, A.1
Tanczos, E.2
Vanscheidt, W.3
Schopf, E.4
Simon, J.C.5
-
11
-
-
33751270222
-
Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective
-
Gotte M., Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006, 66(21):10233-10237.
-
(2006)
Cancer Res.
, vol.66
, Issue.21
, pp. 10233-10237
-
-
Gotte, M.1
Yip, G.W.2
-
12
-
-
20144385541
-
Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2
-
Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 2005, 280(21):20310-20315.
-
(2005)
J. Biol. Chem.
, vol.280
, Issue.21
, pp. 20310-20315
-
-
Misra, S.1
Ghatak, S.2
Toole, B.P.3
-
13
-
-
0028216487
-
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development
-
Bartolazzi A., Peach R., Aruffo A., Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 1994, 180(1):53-66.
-
(1994)
J. Exp. Med.
, vol.180
, Issue.1
, pp. 53-66
-
-
Bartolazzi, A.1
Peach, R.2
Aruffo, A.3
Stamenkovic, I.4
-
14
-
-
0027978978
-
Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells
-
Asplund T., Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 1994, 54(16):4516-4523.
-
(1994)
Cancer Res.
, vol.54
, Issue.16
, pp. 4516-4523
-
-
Asplund, T.1
Heldin, P.2
-
15
-
-
0034986101
-
Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting
-
Sugahara S., Okuno S., Yano T., Hamana H., Inoue K. Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol. Pharm. Bull. 2001, 24(5):535-543.
-
(2001)
Biol. Pharm. Bull.
, vol.24
, Issue.5
, pp. 535-543
-
-
Sugahara, S.1
Okuno, S.2
Yano, T.3
Hamana, H.4
Inoue, K.5
-
16
-
-
0026561154
-
Water-soluble polysaccharide-anthracycline conjugates: biological activity
-
Cera C., Palumbo M., Stefanelli S., Rassu M., Palu G. Water-soluble polysaccharide-anthracycline conjugates: biological activity. Anticancer Drug Des. 1992, 7(2):143-151.
-
(1992)
Anticancer Drug Des.
, vol.7
, Issue.2
, pp. 143-151
-
-
Cera, C.1
Palumbo, M.2
Stefanelli, S.3
Rassu, M.4
Palu, G.5
-
17
-
-
9344229753
-
Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity
-
Akima K., Ito H., Iwata Y., Matsuo K., Watari N., Yanagi M., Hagi H., Oshima K., Yagita A., Atomi Y., Tatekawa I. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J. Drug Target. 1996, 4(1):1-8.
-
(1996)
J. Drug Target.
, vol.4
, Issue.1
, pp. 1-8
-
-
Akima, K.1
Ito, H.2
Iwata, Y.3
Matsuo, K.4
Watari, N.5
Yanagi, M.6
Hagi, H.7
Oshima, K.8
Yagita, A.9
Atomi, Y.10
Tatekawa, I.11
-
18
-
-
0033200301
-
Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate
-
Luo Y., Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 1999, 10(5):755-763.
-
(1999)
Bioconjug. Chem.
, vol.10
, Issue.5
, pp. 755-763
-
-
Luo, Y.1
Prestwich, G.D.2
-
19
-
-
0034897891
-
Hydrogels for combination delivery of antineoplastic agents
-
Bouhadir K.H., Alsberg E., Mooney D.J. Hydrogels for combination delivery of antineoplastic agents. Biomaterials 2001, 22(19):2625-2633.
-
(2001)
Biomaterials
, vol.22
, Issue.19
, pp. 2625-2633
-
-
Bouhadir, K.H.1
Alsberg, E.2
Mooney, D.J.3
-
20
-
-
40849085410
-
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking
-
Xu X., Sutak R., Richardson D.R. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol. Pharmacol. 2008, 73(3):833-844.
-
(2008)
Mol. Pharmacol.
, vol.73
, Issue.3
, pp. 833-844
-
-
Xu, X.1
Sutak, R.2
Richardson, D.R.3
-
21
-
-
43549084331
-
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate
-
Cai S., Xie Y., Bagby T., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J. Surg. Res. 2008, 147(2):247-252.
-
(2008)
J. Surg. Res.
, vol.147
, Issue.2
, pp. 247-252
-
-
Cai, S.1
Xie, Y.2
Bagby, T.3
Cohen, M.S.4
Forrest, M.L.5
-
22
-
-
67549104172
-
Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations
-
Al-Ghananeem A.H.M.A.M., Muammer Y.M., Balko J.M., Black E.P., Mourad W., Romond E. Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech 2009, 10(2):410-417.
-
(2009)
AAPS PharmSciTech
, vol.10
, Issue.2
, pp. 410-417
-
-
Al-Ghananeem, A.H.M.A.M.1
Muammer, Y.M.2
Balko, J.M.3
Black, E.P.4
Mourad, W.5
Romond, E.6
-
23
-
-
0347285397
-
Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models
-
Peer R.M.D. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108(5):780-789.
-
(2004)
Int. J. Cancer
, vol.108
, Issue.5
, pp. 780-789
-
-
Peer, R.M.D.1
-
24
-
-
36749030021
-
Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin
-
Yadav A.K., Mishra P., Mishra A.K., Jain S., Agrawal G.P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 2007, 3(4):246-257.
-
(2007)
Nanomedicine
, vol.3
, Issue.4
, pp. 246-257
-
-
Yadav, A.K.1
Mishra, P.2
Mishra, A.K.3
Jain, S.4
Agrawal, G.P.5
-
25
-
-
47649103158
-
Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin
-
Yadav A.K., Mishra P., Jain S., Mishra A.K., Agrawal G.P. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J. Drug Target. 2008, 16(6):464-478.
-
(2008)
J. Drug Target.
, vol.16
, Issue.6
, pp. 464-478
-
-
Yadav, A.K.1
Mishra, P.2
Jain, S.3
Mishra, A.K.4
Agrawal, G.P.5
-
26
-
-
66849083442
-
Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin
-
Lee H., Ahn C.H., Park T.G. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol. Biosci. 2009, 9(4):336-342.
-
(2009)
Macromol. Biosci.
, vol.9
, Issue.4
, pp. 336-342
-
-
Lee, H.1
Ahn, C.H.2
Park, T.G.3
-
27
-
-
41349087510
-
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin
-
Soloman R., Gabizon A.A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma 2008, 8(1):21-32.
-
(2008)
Clin. Lymphoma Myeloma
, vol.8
, Issue.1
, pp. 21-32
-
-
Soloman, R.1
Gabizon, A.A.2
-
28
-
-
34547852276
-
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)
-
Lorusso D., Stefano A.D., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol. 2007, 18(7):1159-1164.
-
(2007)
Ann. Oncol.
, vol.18
, Issue.7
, pp. 1159-1164
-
-
Lorusso, D.1
Stefano, A.D.2
Carone, V.3
Fagotti, A.4
Pisconti, S.5
Scambia, G.6
-
29
-
-
11144357506
-
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
-
O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15(3):440-449.
-
(2004)
Ann. Oncol.
, vol.15
, Issue.3
, pp. 440-449
-
-
O'Brien, M.E.1
Wigler, N.2
Inbar, M.3
Rosso, R.4
Grischke, E.5
Santoro, A.6
Catane, R.7
Kieback, D.G.8
Tomczak, P.9
Ackland, S.P.10
Orlandi, F.11
Mellars, L.12
Alland, L.13
Tendler, C.14
-
30
-
-
33645081204
-
Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions
-
Wallemacq P.E., Capron A., Vanbinst R., Boeckmans E., Gillard J., Favier B. Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions. Am. J. Health Syst. Pharm. 2006, 63(6):547-556.
-
(2006)
Am. J. Health Syst. Pharm.
, vol.63
, Issue.6
, pp. 547-556
-
-
Wallemacq, P.E.1
Capron, A.2
Vanbinst, R.3
Boeckmans, E.4
Gillard, J.5
Favier, B.6
-
31
-
-
0025051505
-
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
-
Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990, 4(13):3076-3086.
-
(1990)
FASEB J.
, vol.4
, Issue.13
, pp. 3076-3086
-
-
Olson, R.D.1
Mushlin, P.S.2
-
32
-
-
20044376571
-
In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment
-
Quesada A.J., Nelius T., Yap R., Zaichuk T.A., Alfranca A., Filleur S., Volpert O.V., Redondo J.M. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ. 2005, 12(6):649-658.
-
(2005)
Cell Death Differ.
, vol.12
, Issue.6
, pp. 649-658
-
-
Quesada, A.J.1
Nelius, T.2
Yap, R.3
Zaichuk, T.A.4
Alfranca, A.5
Filleur, S.6
Volpert, O.V.7
Redondo, J.M.8
-
33
-
-
10744233861
-
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy
-
Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63(21):7400-7409.
-
(2003)
Cancer Res.
, vol.63
, Issue.21
, pp. 7400-7409
-
-
Pastorino, F.1
Brignole, C.2
Marimpietri, D.3
Cilli, M.4
Gambini, C.5
Ribatti, D.6
Longhi, R.7
Allen, T.M.8
Corti, A.9
Ponzoni, M.10
|